Desarrollo de modelos experimentales murinos para la evaluación preclínica de nuevos tratamientos en tumores hematológicos

Abstract

Multiple myeloma is a hematological malignancy characterized for the accumulation of plasma cells in the bone marrow. It accounts for 1% of all cancers and the prevalence continues to increase due to the ageing population. Despite the progress in novel therapies over the last years, multiple myeloma still remains an incurable disease, because most of the patients progress and develop drug resistances. Mitochondria plays a key role in the development and acquisition of a malignant phenotype in hematological cancers, as well as resistance to therapies; however, is still unknown the role played in the pathogenesis of multiple myeloma. Moreover, growing cancer cells show certain metabolic features resultant of oncogenes dysregulation. In multiple myeloma many of the recurrent chromosomal alterations result in the aberrant expression of oncogenes such as MYC (e.g. translocations). Metabolic changes that occur in patients with multiplemyeloma are directly affected by therapies, which suggests the possibility to interfere anti-myeloma therapies exploiting altered metabolic pathways...